Jubiglim MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, thereby attenuating postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Jubiglim MV 1 Tablet SR is indicated for patients inadequately controlled by diet, exercise, and monotherapy, offering a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of diabetes. It should be used under medical supervision with regular monitoring of blood glucose and renal function. Caution is advised in patients with hepatic or renal impairment, and potential adverse effects include gastrointestinal disturbances, hypoglycemia, and lactic acidosis. This combination therapy aids in achieving optimal glycemic control, reducing the risk of diabetes-related complications.